Logicbio Therapeutics (LOGC) Gets a Buy Rating from Chardan Capital
Markets In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Logicbio Therapeutics (LOGC – Research Report), with a price target of $20.00. The company’s shares closed last Tuesday at $6.10. According to TipRanks.com, Livshits is a top 100 analyst with an average return of 78.0% and a 71.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Intellia Therapeutics. Logicbio Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.00. Logi...